Blood test may end painful bone marrow biopsies for myeloma patients

NCT ID NCT07691034

Not yet recruiting Knowledge-focused Sponsor: Odense University Hospital Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study tests whether a blood test using mass spectrometry can detect minimal residual disease (tiny amounts of cancer left after treatment) in multiple myeloma patients. Currently, doctors must take bone marrow samples, which is painful and inconvenient. The blood test would be easier and could be done more often. Researchers will compare the blood test results with standard bone marrow tests and PET scans in 40 patients who are in deep remission.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could replace painful bone marrow biopsies with a simple blood test for monitoring multiple myeloma remission.
What could go wrong: This is a small, early-stage study. The blood test may not be sensitive enough to catch all residual cancer cells, and results need validation in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MINIMAL RESIDUAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Neoplasm, Residual plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MINIMAL RESIDUAL DISEASE MULTIPLE MYELOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.